Six Reasons Why CVS Health Should Acquire Aetna … Soon

Posted by Tarun Mehra

Jun 21, 2017 10:00:00 AM

Should CVS consider acquiring a health plan? If yes, then which one? With a market-cap of about $80 billion and an impressive portfolio of assets across retail and pharmacy, why would it make sense for CVS to include a health plan in its portfolio?

Read More

Topics: Brand Insights, Healthcare, Merger and Acquisition, Competitive Strategy

Upcoming Event: Ken Sawka Speaking at BU Questrom Health & Life Sciences Conference October 14th

Posted by Fuld + Company

Oct 12, 2016 1:40:45 PM

On Friday, October 14th, Fuld + Company CEO, Ken Sawka, is speaking at the Boston University Questrom School of Business's fourth annual Health & Life Sciences Conference. 

The Health & Life Sciences Conference is an annual, student-organized event that brings together a diverse audience of more than 350 students and professionals across all sectors of the US healthcare industry for valuable networking and comprehensive programming spanning from healthcare delivery and hospitals to pharmaceuticals and medical devices.

Read More

Topics: Events, Healthcare, Life Sciences

Defending Market Share in Pharma

Posted by Fuld + Company

Mar 18, 2016 9:49:49 AM

Pharmaceutical firms frequently need to defend their market position against rivals’ competitive strategy. Threats to leading therapies can come in many forms:

Read More

Topics: Competitive Intelligence, Fuld + Company, Pharma, Healthcare, Life Cycle Management, Life Sciences, Competitive Strategy

The Rise of Mobile Healthcare Payments

Posted by Tess Fagan

Mar 9, 2016 10:07:12 AM

2016 has been dubbed the year of mobile payments. From Venmo to Samsung Pay, the phone is replacing the wallet. Spending money, whether to buy a latte or to split a check, has never been easier. 2016 is also the year many legislative healthcare reforms solidify their effect, modernizing everything from how hospitals store records to which models we use to fund health care.

The changing nature of health care is fueling innovation. Tech companies and start-ups are beginning to develop payment solutions to meet the evolving needs of healthcare payers and providers, driven in part by legislation but also by rapidly accelerating consumerization trends. Just in time: enjoying how simple it's become to pay for everything else, consumers are growing frustrated by the difficulty of navigating healthcare payments. Healthcare providers who make the switch to electronic payments early can gain a competitive edge.

The race to become the leading payment system for the healthcare industry is on.

Read More

Topics: Innovation, Market Analysis, Technology/Telecomm, Healthcare, Industry Convergence, Competitive Strategy

Medical Education and the Affordable Care Act

Posted by Fuld + Company

Jan 28, 2016 10:32:17 AM

Ken Sawka   | Jacob Golbitz 

Perhaps it was inevitable. Kaiser Permanente, the California-based health system that integrates health insurance with its own hospitals and clinics, last month announced that it would open its own medical school in the state in 2019. 

The move underscores two factors that have bedeviled healthcare reform in the United States before and after the passage of the Affordable Care Act in 2010 – a forecasted shortage of physicians in the United States, and the failure of traditional medical education to keep pace with the training required to enable physicians to provide healthcare in an integrated, risk-based system.

Read More

Topics: Competitive Intelligence, Innovation, Market Analysis, Healthcare, Life Sciences

New Video! Building a Life Sciences CI Team

Posted by Fuld + Company

Dec 15, 2015 9:50:08 AM

Finding the right talent to fill CI needs at a Life Sciences company can be challenging. From companion diagnostics to biosimilars, it's a complex marketplace that requires highly skilled CI practitioners.

David Staknis, Principal, Practice Head Global Life Sciences, and Ken Sawka, CEO + President, discuss necessary industry experience and academic qualifications for inclusion in a CI team, as well as team dynamics within Fuld + Company's own Life Sciences practice.

Read More

Topics: Competitive Intelligence, Fuld + Company, Pharma, Healthcare, Life Sciences

New Video! Companion Diagnostics

Posted by Fuld + Company

Dec 11, 2015 8:00:00 AM

Companion diagnostic (CDx) devices are in vitro and imaging tools that are paired with specific drug therapies. Part of a larger trend towards personalized medicine, they are used to identify patients most likely to benefit from a specific therapeutic agent or to determine appropriate dosage. 

While questions remain about who should bear the cost for companion diagnostics, the promise of greater safety and efficacy and the potential for faster regulatory approval have made this an area of growth for both pharmaceutical and molecular diagnostics clients.

David Staknis, Principal, Practice Head Global Life Sciences, and Ken Sawka, CEO + President, discuss increased requests for monitoring development and expansion of CDx platforms, earlier coordination by pharmaceutical and diagnostics firms, and the benefits of CI for optimizing R&D spending.

Read More

Topics: Competitive Intelligence, Early Warning Monitoring, Medical Devices, Pharma, Healthcare, Life Sciences

New White Paper! New Strategies for Health Care Industry Convergence

Posted by Fuld + Company

Nov 23, 2015 8:00:00 AM


Consumer retail, enterprise IT, consumer electronics, health insurance, and health care delivery are rapidly converging to improve the customer/patient experience. 

Relying on tried and true approaches to strategy development may no longer be good enough when multiple markets collide. As health care delivery, payment, and reporting evolve in response to shifts in demographics, technology, and political influence, population health management becomes the key to controlling costs.

Read More

Topics: Fuld + Company, Market Analysis, Scenario Analysis, Technology/Telecomm, Healthcare, Industry Convergence, Competitive Strategy

Jack Bauer and the Flu

Posted by Robert Flynn

Oct 23, 2015 6:49:12 AM

On February 5, 2015, Public Health England announced that the flu vaccine had demonstrated low effectiveness against the main strain of flu that had circulated this past winter. Dr. Michael Skinner of Imperial College London, said in response, “Trying to predict which seasonal flu vaccine to produce each year must be a bit like a Jack Bauer car chase in Los Angeles…bound to prove somewhat hit & miss.” 

A similar miss occurred in 2004, when the United States suspended The Chiron Corporation’s shipment of 48 million doses of vaccine, citing problems at the company’s Liverpool, England, manufacturing plant.

Read More

Topics: Brand Insights, Market Analysis, Pharma, Scenario Analysis, Healthcare, Life Sciences, Merger and Acquisition

Upcoming Event: Fuld + Co. Speaking at Health Innovators' Panel Thursday

Posted by Fuld + Company

Oct 19, 2015 4:39:07 PM

Alexis Kuchins - VP, Life Sciences Business Development - joins a panel of strategists, marketers, and researchers at "Marketing Healthcare Innovations: Know Your Customer, Know Opportunity" this Thursday in Cambridge. 

Topics to be covered include: 

  • Gathering customer intelligence to guide product design and uncover value 
  • Uncovering what investors or development partner organizations are looking for 
  • Knowing your competition to better know yourself 

Read More

Topics: Events, Fuld + Company, Innovation, Healthcare

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.